Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib study of GDC-6036 alone and in combinations for KRAS G12C-mutated advanced solid tumors
NL-OMON56305Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of divarasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (5 arms), sponsored by Genentech. Started Sep 2021; status: recruiting.
02
Drugs
divarasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON56305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56305.